QCG
KRYS icon

Quadrant Capital Group’s Krystal Biotech KRYS Stock Holding History

Quadrant Capital Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61K Buy
236
+80
+51% +$21.3K ﹤0.01% 1635
2025
Q4 		$38.5K Buy
156
+20
+15% +$4.21K ﹤0.01% 1777
2025
Q3 		$24K Buy
+136
New +$20.4K ﹤0.01% 1893
2025
Q2 		– Sell
-3,883
Closed -$700K – 2017
2025
Q1 		$700K Buy
3,883
+3,726
+2,373% +$627K 0.03% 539
2024
Q4 		$24.6K Sell
157
-260
-62% -$46.1K ﹤0.01% 1790
2024
Q3 		$75.9K Buy
417
+343
+464% +$66.1K 0.01% 1233
2024
Q2 		$13.6K Buy
74
+39
+111% +$6.55K ﹤0.01% 2010
2024
Q1 		$6.23K Sell
35
-10
-22% -$1.39K ﹤0.01% 2254
2023
Q4 		$5.58K Buy
45
+10
+29% +$1.11K ﹤0.01% 2247
2023
Q3 		$4.06K Hold
35
– – ﹤0.01% 2225
2023
Q2 		$4.11K Hold
35
– – ﹤0.01% 2251
2023
Q1 		$2.8K Buy
+35
New +$2.75K ﹤0.01% 2365
2022
Q3 		– Sell
-4
Closed – – 2723
2022
Q2 		$0 Hold
4
– – ﹤0.01% 2636
2022
Q1 		$0 Sell
4
-17
-81% -$1.06K ﹤0.01% 2597
2021
Q4 		$1K Buy
+21
New +$1.22K ﹤0.01% 2326

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's KRYS Position: Q1 2026 in Review

Quadrant Capital Group increased its Krystal Biotech (KRYS) stake by 51% in Q1 2026, buying an estimated $21.3K and bringing the position to 236 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

Quadrant Capital Group first reported a position in KRYS in Q4 2021 and has held it in 15 quarters since. The position peaked at $700K in Q1 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Quadrant Capital Group held 236 shares of Krystal Biotech worth $61K as of Q1 2026.
  • Quadrant Capital Group bought 80 Krystal Biotech shares in Q1 2026, an estimated $21.3K.
  • Krystal Biotech made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1635 holding.
  • Quadrant Capital Group first reported a position in Krystal Biotech in Q4 2021 and has held it in 15 quarters since.
  • Quadrant Capital Group's Krystal Biotech position peaked at $700K in Q1 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.